Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. For more information, please visit www.PAXLOVID.com. .

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

JANUARY 21, 2021

Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. PT) Presentation Number: MA13.07. Access to the presentations is available to members of IASLC and can be found here: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Containment Licensing 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. based Horizon Discovery Group granted a license to China’s Sanyou Biopharmaceuticals Co. in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

pharmaphorum

SEPTEMBER 8, 2022

However, there is a difference between the two: the toxic payloads of ADCs need to be absorbed into cancer cells, whereas radiopharmaceuticals can still do damage even when only bound to the cancer, and are particularly sensitive to radiation-induced DNA damage. Investment is flowing.

Manufacturing 105

Manufacturing Development Antibody Drugs 105

Roots Analysis

FEBRUARY 15, 2022

Specifically, the multi-step process of production of cytotoxic payloads, which are used in ADCs, requires a contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities. Want additional details on the ADC Payloads / Warheads Developers? Increased Partnership Activity.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

The Pharma Data

AUGUST 17, 2021

Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. About Mismatch Repair Deficiency In normal cells, mismatch repair (MMR) is a process that corrects errors introduced during DNA replication via enzymes.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

AUGUST 3, 2021

Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. We are powered by the world’s largest, commercially-proven gene therapy manufacturing footprint, enabling us to bring gene therapy to patients around the world at quality and scale.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Therapy Gene 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.

Marketing 75

Marketing Production Drugs Licensing 75

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. For more information, please visit www.PAXLOVID.com.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

OCTOBER 19, 2020

CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. Any forward-looking statements contained in this press release speak only as of its date. . . SOURCE CNS Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

The Pharma Data

DECEMBER 16, 2020

CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. Any forward-looking statements contained in this press release speak only as of its date. For more information, please visit www.CNSPharma.com. .

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

The gene therapy utilizes an AAV1 viral vector to deliver a modified DNA encoding the GRN gene to a patient’s cells. Passage Bio is developing PBFT02 to treat FTD-GRN as a single dose delivered via intra-cisterna magna (ICM) injection. More information is available at www.passagebio.com. Forward-Looking Statements.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. FDA Emergency Use Authorization Statement. anti-infectives).

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Our Commitment to Access. Disclosure Notice.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

JANUARY 21, 2021

INSTIs, like cabotegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). Trademarks are owned by or licensed to Janssen and the ViiV Healthcare group of companies. Janssen is the marketing authorization holder for EDURANT ® in the U.S.

FDA Approval 52

FDA Approval RNA Drugs Containment 52

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 20, 2020

The therapy is remestemcel-L, which contains culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. Graphite Bio licensed the product from Stanford University.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Numbers may not add due to rounding.

Antibody 52

Antibody Sales Development Production 52

Druggist

OCTOBER 13, 2020

Truvada is also licensed as pre-exposure prophylaxis (PrEP) medication. Truvada is a brand name of a combination drug, which contains two antiviral medicines: emtricitabine and tenofovir disoproxil. In plain language, both emtricitabine and tenofovir disoproxil stops viral DNA production and therefore stops spreading of HIV.

Generic Drugs 98

Generic Drugs Pharmacy Branding Doctors 98